Evidence of polyclonal hematopoiesis in a large proportion of patients with low-risk myelodysplastic syndrome.

被引：0
|
作者：
Malcovati, L
Della Porta, MG
Galli, A
Boggi, S
Malabarba, L
Pietra, D
Passamonti, F
Bergamaschi, G
Lazzarino, M
Cazzola, M
机构：
[1] Univ Pavia, Div Hematol, Sch Med, I-27100 Pavia, Italy
[2] Policlin San Matteo, IRCCS, I-27100 Pavia, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2364
引用
收藏
页码：649A / 650A
页数：2
相关论文
共 50 条
  • [21] SWITCHING TO AN ALTERNATIVE RECOMBINANT ERYTHROPOIETIN AGENT MAY BE EFFECTIVE IN PATIENTS WITH LOW-RISK MYELODYSPLASTIC SYNDROME
    Fattizzo, B.
    Rizzo, L.
    Giannotta, J. A.
    Cecchi, N.
    Mazzon, F.
    Barcellini, W.
    Riva, M.
    HAEMATOLOGICA, 2021, 106 (10) : 173 - 173
  • [22] Utilization Patterns and Outcomes from Iron Chelation in Elderly Patients with Low-Risk Myelodysplastic Syndrome
    Herrera, Diego Adrianzen
    Sparks, Andrew
    Singh, Rohit
    Giorgio, Katherine
    Lutsey, Pamela
    Zakai, Neil
    BLOOD, 2023, 142
  • [23] Treatment of myelodysplastic syndrome (MDS) with cytokine immunotherapy for low-risk MDS
    Kadia, Tapan M.
    Kantadian, Hagop
    Verstovsek, Srdan
    Newman, Beth
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    BLOOD, 2007, 110 (11) : 438A - 438A
  • [24] New aspects of the treatment of patients with low-risk myelodysplastic syndromes
    Hofmann, WK
    Seipelt, G
    Kalina, U
    Hoelzer, D
    ONKOLOGIE, 2000, 23 (01): : 12 - 16
  • [25] Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
    Vicente, Alana
    Patel, Bhavisha A.
    Gutierrez-Rodrigues, Fernanda
    Groarke, Emma M.
    Giudice, Valentina
    Lotter, Jennifer
    Feng, Xingmin
    Kajigaya, Sachiko
    Weinstein, Barbara
    Barranta, Evette
    Olnes, Matthew J.
    Parikh, Ankur R.
    Albitar, Maher
    Wu, Colin O.
    Shalhoub, Ruba
    Calvo, Katherine R.
    Townsley, Danielle M.
    Scheinberg, Phillip
    Dunbar, Cynthia E.
    Young, Neal S.
    Winkler, Thomas
    HAEMATOLOGICA, 2020, 105 (12) : 2785 - 2794
  • [26] Treatment of low-risk myelodysplastic syndromes
    Santini, Valeria
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 462 - 469
  • [27] Ineffective hematopoiesis linked with a mitochondrial tRNA mutation in a patient with myelodysplastic syndrome.
    Gattermann, N
    Wulfert, M
    Junge, B
    Germing, U
    Haas, R
    Hofhaus, G
    BLOOD, 2003, 102 (11) : 326B - 327B
  • [28] RECOVERY OF POLYCLONAL HEMATOPOIESIS IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FOLLOWING SUCCESSFUL CHEMOTHERAPY
    ITO, T
    OHASHI, H
    KAGAMI, Y
    ICHIKAWA, A
    SAITO, H
    HOTTA, T
    LEUKEMIA, 1994, 8 (05) : 839 - 843
  • [29] Outcome of Patients With Low-Risk and Intermediate-1-Risk Myelodysplastic Syndrome After Hypomethylating Agent Failure
    Jabbour, Elias J.
    Garcia-Manero, Guillermo
    Strati, Paolo
    Mishra, Asmita
    Al Ali, Najla H.
    Padron, Eric
    Lancet, Jeffrey
    Kadia, Tapan
    Daver, Naval
    O'Brien, Susan
    Steensma, David P.
    Sekeres, Mikkael A.
    Gore, Steven D.
    Dezern, Amy
    Roboz, Gail J.
    List, Alan F.
    Kantarjian, Hagop M.
    Komrokji, Rami S.
    CANCER, 2015, 121 (06) : 876 - 882
  • [30] Micrornas Analysis in Patients with Myelodysplastic Syndrome. Possible Implications in Risk Stratification
    Kontandreopoulou, Christina-Nefeli
    Syriopoulou, Stavroula
    Diamantopoulos, Panagiotis T.
    Giannakopoulou, Nefeli
    Vlachopoulou, Dimitra
    Katsiampoura, Panagiota
    Stafylidis, Christos
    Dimou, Maria
    Galanopoulos, Athanasios
    Papageorgiou, Sotirios
    Hatzimichael, Eleftheria
    Pappa, Vassiliki
    Ioannis, Kotsianidis
    Symeonidis, Argiris
    Panayiotidis, Panayiotis
    Viniou, Nora-Athina
    BLOOD, 2022, 140 : 6958 - 6959
12345